Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


11.02.2019

1 BMC Cancer
1 Br J Cancer
1 Cancer Chemother Pharmacol
1 Cancer Res
8 Gynecol Oncol
2 Hum Pathol
2 Int J Cancer
3 Oncol Rep
1 Oncology
1 Proc Natl Acad Sci U S A


   Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. YOUNG EL, Thompson BA, Neklason DW, Firpo MA, et al
    Pancreatic cancer as a sentinel for hereditary cancer predisposition.
    BMC Cancer. 2018;18:697.
    PubMed     Text format     Abstract available


    Br J Cancer

  2. WESTERGAARD MCW, Andersen R, Chong C, Kjeldsen JW, et al
    Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
    Br J Cancer. 2019 Feb 5. pii: 10.1038/s41416-019-0384.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  3. VAN ANDEL L, Rosing H, Zhang Z, Hughes L, et al
    Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients.
    Cancer Chemother Pharmacol. 2018;81:39-46.
    PubMed     Text format     Abstract available


    Cancer Res

  4. CHOI J, Brown KM
    A Dynamic Cis-Regulation Pattern Underlying Epithelial Ovarian Cancer Susceptibility.
    Cancer Res. 2019;79:439-440.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  5. SULLIVAN MW, Camacho FT, Mills AM, Modesitt SC, et al
    Missing information in statewide and national cancer databases: Correlation with health risk factors, geographic disparities, and outcomes.
    Gynecol Oncol. 2019;152:119-126.
    PubMed     Text format     Abstract available

  6. TURASHVILI G, Gomez-Hidalgo NR, Flynn J, Gonen M, et al
    Risk-based stratification of carcinomas concurrently involving the endometrium and ovary.
    Gynecol Oncol. 2018 Nov 6. pii: S0090-8258(18)31315.
    PubMed     Text format     Abstract available

  7. ROMEO C, Joly F, Ray-Coquard I, El Kouri C, et al
    Non-pegylated liposomal doxorubicin (NPLD, Myocet(R))+carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.
    Gynecol Oncol. 2018 Nov 14. pii: S0090-8258(18)31358.
    PubMed     Text format     Abstract available

  8. ORSULIC S, Karlan BY
    Can molecular subtyping be used to triage women with advanced ovarian cancer to Primary Debulking Surgery or Neoadjuvant Chemotherapy?
    Gynecol Oncol. 2019;152:221-222.
    PubMed     Text format    

  9. HOSKINS P, Eccleston A, Hurry M, Dyer M, et al
    Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.
    Gynecol Oncol. 2019 Jan 28. pii: S0090-8258(19)30061.
    PubMed     Text format     Abstract available

  10. VOGEL RI, Niendorf K, Petzel S, Lee H, et al
    A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: A pilot randomized controlled trial.
    Gynecol Oncol. 2019 Feb 1. pii: S0090-8258(19)30062.
    PubMed     Text format     Abstract available

  11. LIM SL, Havrilesky LJ, Habib AS, Secord AA, et al
    Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy.
    Gynecol Oncol. 2019 Feb 1. pii: S0090-8258(19)30067.
    PubMed     Text format     Abstract available

  12. SUSZYNSKA M, Klonowska K, Jasinska AJ, Kozlowski P, et al
    Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.
    Gynecol Oncol. 2019 Feb 4. pii: S0090-8258(19)30069.
    PubMed     Text format     Abstract available


    Hum Pathol

  13. XING D, Banet N, Sharma R, Vang R, et al
    Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study.
    Hum Pathol. 2018;72:160-166.
    PubMed     Text format     Abstract available

  14. ESPINOSA I, De Leo A, D'Angelo E, Rosa-Rosa JM, et al
    Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Hum Pathol. 2017 Nov 10. pii: S0046-8177(17)30413.
    PubMed     Text format     Abstract available


    Int J Cancer

  15. AGOSTINI A, Brunetti M, Davidson B, Trope CG, et al
    Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas.
    Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31418.
    PubMed     Text format     Abstract available

  16. CHAN KK, Wong OG, Wong ES, Chan KK, et al
    Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31535.
    PubMed     Text format     Abstract available


    Oncol Rep

  17. WANG P, Zhang J, Xiong X, Yuan W, et al
    Icariin suppresses cell cycle transition and cell migration in ovarian cancer cells.
    Oncol Rep. 2019 Jan 28. doi: 10.3892/or.2019.6986.
    PubMed     Text format     Abstract available

  18. ALVES MR, Do Amaral NS, Marchi FA, Silva FIB, et al
    Prostaglandin D2 expression is prognostic in highgrade serous ovarian cancer.
    Oncol Rep. 2019 Jan 28. doi: 10.3892/or.2019.6984.
    PubMed     Text format     Abstract available

  19. ZOU M, Hu X, Xu B, Tong T, et al
    Glutathione Stransferase isozyme alpha 1 is predominantly involved in the cisplatin resistance of common types of solid cancer.
    Oncol Rep. 2019;41:989-998.
    PubMed     Text format     Abstract available


    Oncology

  20. MIYAMOTO M, Takano M, Tsuda H, Matuura H, et al
    Zone Formation of Lymphocyte Infiltration at Invasive Front as a Biomarker of Prognosis in Endometrial Carcinomas.
    Oncology. 2019;96:93-100.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  21. WU X, Luo Q, Zhao P, Chang W, et al
    MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer.
    Proc Natl Acad Sci U S A. 2019 Feb 4. pii: 1814742116.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: